Skip to main content
Top
Published in: Cancer Imaging 1/2024

Open Access 01-12-2024 | Magnetic Resonance Imaging | Research article

MRI evaluation of vesical imaging reporting and data system for bladder cancer after neoadjuvant chemotherapy

Authors: Xinxin Zhang, Yichen Wang, Yilin Wang, Jie Zhang, Jin Zhang, Lianyu Zhang, Sicong Wang, Jianzhong Shou, Yan Chen, Xinming Zhao

Published in: Cancer Imaging | Issue 1/2024

Login to get access

Abstract

Background

The Vesical Imaging-Reporting and Data System (VI-RADS) has demonstrated effectiveness in predicting muscle invasion in bladder cancer before treatment. The urgent need currently is to evaluate the muscle invasion status after neoadjuvant chemotherapy (NAC) for bladder cancer. This study aims to ascertain the accuracy of VI-RADS in detecting muscle invasion post-NAC treatment and assess its diagnostic performance across readers with varying experience levels.

Methods

In this retrospective study, patients with muscle-invasive bladder cancer who underwent magnetic resonance imaging (MRI) after NAC from September 2015 to September 2018 were included. VI-RADS scores were independently assessed by five radiologists, consisting of three experienced in bladder MRI and two inexperienced radiologists. Comparison of VI-RADS scores was made with postoperative histopathological diagnosis. Receiver operating characteristic curve analysis (ROC) was used for evaluating diagnostic performance, calculating sensitivity, specificity, and area under ROC (AUC)). Interobserver agreement was assessed using the weighted kappa statistic.

Results

The final analysis included 46 patients (mean age: 61 years ± 9 [standard deviation]; age range: 39–70 years; 42 men). The pooled AUC for predicting muscle invasion was 0.945 (95% confidence interval (CI): 0.893–0.977) for experienced readers, and 0.910 (95% CI: 0.831–0.959) for inexperienced readers, and 0.932 (95% CI: 0.892–0.961) for all readers. At an optimal cut-off value ≥ 4, pooled sensitivity and specificity were 74.1% (range: 66.0–80.9%) and 94.1% (range: 88.6–97.7%) for experienced readers, and 63.9% (range: 59.6–68.1%) and 86.4% (range: 84.1–88.6%) for inexperienced readers. Interobserver agreement ranged from substantial to excellent between all readers (k = 0.79–0.92).

Conclusions

VI-RADS accurately assesses muscle invasion in bladder cancer patients after NAC and exhibits good diagnostic performance across readers with different experience levels.
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
go back to reference Smith AB, Deal AM, Woods ME, Wallen EM, Pruthi RS, Chen RC, et al. Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base. BJU Int. 2014;114(5):719–26.CrossRefPubMed Smith AB, Deal AM, Woods ME, Wallen EM, Pruthi RS, Chen RC, et al. Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base. BJU Int. 2014;114(5):719–26.CrossRefPubMed
3.
go back to reference Flaig TW. NCCN Guidelines Updates: Management of Muscle-Invasive Bladder Cancer. J Natl Compr Canc Netw. 2019;17(5.5):591–3.PubMed Flaig TW. NCCN Guidelines Updates: Management of Muscle-Invasive Bladder Cancer. J Natl Compr Canc Netw. 2019;17(5.5):591–3.PubMed
4.
go back to reference Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018;391(10139):2525–36.CrossRefPubMed Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018;391(10139):2525–36.CrossRefPubMed
5.
go back to reference Yu HY, Hevelone ND, Lipsitz SR, Kowalczyk KJ, Nguyen PL, Choueiri TK, et al. Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol. 2012;61(6):1239–44.CrossRefPubMed Yu HY, Hevelone ND, Lipsitz SR, Kowalczyk KJ, Nguyen PL, Choueiri TK, et al. Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol. 2012;61(6):1239–44.CrossRefPubMed
6.
go back to reference Winters BR, Wright JL, Holt SK, Dash A, Gore JL, Schade GR. Health Related Quality of Life Following Radical Cystectomy: Comparative Analysis from the Medicare Health Outcomes Survey. J Urol. 2018;199(3):669–75.CrossRefPubMed Winters BR, Wright JL, Holt SK, Dash A, Gore JL, Schade GR. Health Related Quality of Life Following Radical Cystectomy: Comparative Analysis from the Medicare Health Outcomes Survey. J Urol. 2018;199(3):669–75.CrossRefPubMed
7.
go back to reference Broughman JR, Vuong W, Mian OY. Current Landscape and Future Directions on Bladder Sparing Approaches to Muscle-Invasive Bladder Cancer. Curr Treat Options Oncol. 2020;22(1):3.CrossRefPubMedPubMedCentral Broughman JR, Vuong W, Mian OY. Current Landscape and Future Directions on Bladder Sparing Approaches to Muscle-Invasive Bladder Cancer. Curr Treat Options Oncol. 2020;22(1):3.CrossRefPubMedPubMedCentral
8.
go back to reference Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017;71(6):952–60.CrossRefPubMed Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017;71(6):952–60.CrossRefPubMed
9.
go back to reference James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–88.CrossRefPubMed James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–88.CrossRefPubMed
10.
go back to reference Herr HW. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2008;54(1):126–32.CrossRefPubMed Herr HW. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2008;54(1):126–32.CrossRefPubMed
11.
go back to reference Sternberg CN, Pansadoro V, Calabrò F, Schnetzer S, Giannarelli D, Emiliozzi P, et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer. 2003;97(7):1644–52.CrossRefPubMed Sternberg CN, Pansadoro V, Calabrò F, Schnetzer S, Giannarelli D, Emiliozzi P, et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer. 2003;97(7):1644–52.CrossRefPubMed
12.
go back to reference Robins D, Matulay J, Lipsky M, Meyer A, Ghandour R, DeCastro G, et al. Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy. Urology. 2018;111:116–21.CrossRefPubMed Robins D, Matulay J, Lipsky M, Meyer A, Ghandour R, DeCastro G, et al. Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy. Urology. 2018;111:116–21.CrossRefPubMed
13.
go back to reference Reese AC, Ball MW, Gandhi N, Gorin MA, Netto GJ, Bivalacqua TJ, et al. The utility of an extensive postchemotherapy staging evaluation in patients receiving neoadjuvant chemotherapy for bladder cancer. Urology. 2014;84(2):358–63.CrossRefPubMed Reese AC, Ball MW, Gandhi N, Gorin MA, Netto GJ, Bivalacqua TJ, et al. The utility of an extensive postchemotherapy staging evaluation in patients receiving neoadjuvant chemotherapy for bladder cancer. Urology. 2014;84(2):358–63.CrossRefPubMed
14.
go back to reference Winoker JS, Liaw CW, Galsky MD, Wiklund P, Mehrazin R. Clinical Complete Response after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Call for Standardized Assessments and Definitions. Eur Urol Focus. 2020;6(4):627–9.CrossRefPubMed Winoker JS, Liaw CW, Galsky MD, Wiklund P, Mehrazin R. Clinical Complete Response after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Call for Standardized Assessments and Definitions. Eur Urol Focus. 2020;6(4):627–9.CrossRefPubMed
15.
go back to reference Kukreja JB, Porten S, Golla V, Ho PL, Noguera-Gonzalez G, Navai N, et al. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Eur Urol Focus. 2018;4(5):720–4.CrossRefPubMed Kukreja JB, Porten S, Golla V, Ho PL, Noguera-Gonzalez G, Navai N, et al. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Eur Urol Focus. 2018;4(5):720–4.CrossRefPubMed
16.
go back to reference Becker REN, Meyer AR, Brant A, Reese AC, Biles MJ, Harris KT, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. 2021;79(3):364–71.CrossRefPubMed Becker REN, Meyer AR, Brant A, Reese AC, Biles MJ, Harris KT, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. 2021;79(3):364–71.CrossRefPubMed
17.
go back to reference Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic performance of MRI for prediction of muscle-invasiveness of bladder cancer: A systematic review and meta-analysis. Eur J Radiol. 2017;95:46–55.CrossRefPubMed Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic performance of MRI for prediction of muscle-invasiveness of bladder cancer: A systematic review and meta-analysis. Eur J Radiol. 2017;95:46–55.CrossRefPubMed
18.
go back to reference Huang L, Kong Q, Liu Z, Wang J, Kang Z, Zhu Y. The Diagnostic Value of MR Imaging in Differentiating T Staging of Bladder Cancer: A Meta-Analysis. Radiology. 2018;286(2):502–11.CrossRefPubMed Huang L, Kong Q, Liu Z, Wang J, Kang Z, Zhu Y. The Diagnostic Value of MR Imaging in Differentiating T Staging of Bladder Cancer: A Meta-Analysis. Radiology. 2018;286(2):502–11.CrossRefPubMed
19.
go back to reference Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. 2018;74(3):294–306.CrossRefPubMedPubMedCentral Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. 2018;74(3):294–306.CrossRefPubMedPubMedCentral
20.
go back to reference Wang H, Luo C, Zhang F, Guan J, Li S, Yao H, et al. Multiparametric MRI for Bladder Cancer: Validation of VI-RADS for the Detection of Detrusor Muscle Invasion. Radiology. 2019;291(3):668–74.CrossRefPubMed Wang H, Luo C, Zhang F, Guan J, Li S, Yao H, et al. Multiparametric MRI for Bladder Cancer: Validation of VI-RADS for the Detection of Detrusor Muscle Invasion. Radiology. 2019;291(3):668–74.CrossRefPubMed
21.
go back to reference Arita Y, Shigeta K, Akita H, Suzuki T, Kufukihara R, Kwee TC, et al. Clinical utility of the Vesical Imaging-Reporting and Data System for muscle-invasive bladder cancer between radiologists and urologists based on multiparametric MRI including 3D FSE T2-weighted acquisitions. Eur Radiol. 2021;31(2):875–83.CrossRefPubMed Arita Y, Shigeta K, Akita H, Suzuki T, Kufukihara R, Kwee TC, et al. Clinical utility of the Vesical Imaging-Reporting and Data System for muscle-invasive bladder cancer between radiologists and urologists based on multiparametric MRI including 3D FSE T2-weighted acquisitions. Eur Radiol. 2021;31(2):875–83.CrossRefPubMed
22.
go back to reference Hagen F, Norz V, Thaiss WM, Mair A, Rausch S, Bedke J, et al. Diagnostic benefit of multiparametric MRI over contrast-enhanced CT in patients with bladder cancer: A single-center 1-year experience. Eur J Radiol. 2022;146: 110059.CrossRefPubMed Hagen F, Norz V, Thaiss WM, Mair A, Rausch S, Bedke J, et al. Diagnostic benefit of multiparametric MRI over contrast-enhanced CT in patients with bladder cancer: A single-center 1-year experience. Eur J Radiol. 2022;146: 110059.CrossRefPubMed
23.
go back to reference Hong SB, Lee NK, Kim S, Son IW, Ha HK, Ku JY, et al. Vesical Imaging-Reporting and Data System for Multiparametric MRI to Predict the Presence of Muscle Invasion for Bladder Cancer. J Magn Reson Imaging. 2020;52(4):1249–56.CrossRefPubMed Hong SB, Lee NK, Kim S, Son IW, Ha HK, Ku JY, et al. Vesical Imaging-Reporting and Data System for Multiparametric MRI to Predict the Presence of Muscle Invasion for Bladder Cancer. J Magn Reson Imaging. 2020;52(4):1249–56.CrossRefPubMed
24.
go back to reference Del Giudice F, Barchetti G, De Berardinis E, Pecoraro M, Salvo V, Simone G, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol. 2020;77(1):101–9.CrossRefPubMed Del Giudice F, Barchetti G, De Berardinis E, Pecoraro M, Salvo V, Simone G, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol. 2020;77(1):101–9.CrossRefPubMed
25.
go back to reference van der Heijden AG, Witjes JA. Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnostics: The Replacement for Surgery? Eur Urol Oncol. 2020;3(3):316–7.CrossRefPubMed van der Heijden AG, Witjes JA. Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnostics: The Replacement for Surgery? Eur Urol Oncol. 2020;3(3):316–7.CrossRefPubMed
26.
go back to reference Del Giudice F, Campa R, Bicchetti M, De Berardinis E, Panebianco V. Vesical Imaging-Reporting and Data System (VI-RADS) incorporated into bladder cancer clinical practice: what’s the perspectives beyond diagnostic accuracy? Transl Androl Urol. 2020;9(5):2320–2.CrossRefPubMedPubMedCentral Del Giudice F, Campa R, Bicchetti M, De Berardinis E, Panebianco V. Vesical Imaging-Reporting and Data System (VI-RADS) incorporated into bladder cancer clinical practice: what’s the perspectives beyond diagnostic accuracy? Transl Androl Urol. 2020;9(5):2320–2.CrossRefPubMedPubMedCentral
27.
go back to reference Cao B, Li Q, Xu P, Chen W, Hu X, Dai C, et al. Preliminary Exploration of the Application of Vesical Imaging-Reporting and Data System (VI-RADS) in Post-treatment Patients With Bladder Cancer: A Prospective Single-Center Study. J Magn Reson Imaging. 2022;55(1):275–86.CrossRefPubMed Cao B, Li Q, Xu P, Chen W, Hu X, Dai C, et al. Preliminary Exploration of the Application of Vesical Imaging-Reporting and Data System (VI-RADS) in Post-treatment Patients With Bladder Cancer: A Prospective Single-Center Study. J Magn Reson Imaging. 2022;55(1):275–86.CrossRefPubMed
28.
go back to reference Yuan B, Cai L, Cao Q, Wu Q, Zhuang J, Sun X, et al. Role of Vesical Imaging-Reporting and Data System in predicting muscle-invasive bladder cancer: A diagnostic meta-analysis. Int J Urol. 2022;29(3):186–95.CrossRefPubMed Yuan B, Cai L, Cao Q, Wu Q, Zhuang J, Sun X, et al. Role of Vesical Imaging-Reporting and Data System in predicting muscle-invasive bladder cancer: A diagnostic meta-analysis. Int J Urol. 2022;29(3):186–95.CrossRefPubMed
30.
go back to reference Cai Q, Ling J, Kong L, Huang Y, Lin Y, Wen Z, et al. Multiparametric MRI Evaluation of VI-RADS for Bladder Tumors Located at the Ureteral Orifice. Radiology. 2022;304(3):593–9.CrossRefPubMed Cai Q, Ling J, Kong L, Huang Y, Lin Y, Wen Z, et al. Multiparametric MRI Evaluation of VI-RADS for Bladder Tumors Located at the Ureteral Orifice. Radiology. 2022;304(3):593–9.CrossRefPubMed
31.
go back to reference Oğuz U, Bekçi T, Öğreden E, Aslan S, Duman A, Demirelli E, et al. Prospective assessment of VI-RADS score in multiparametric MRI in bladder cancer: accuracy and the factors affecting the results. Diagn Interv Radiol. 2022;28(5):396–402.CrossRefPubMedPubMedCentral Oğuz U, Bekçi T, Öğreden E, Aslan S, Duman A, Demirelli E, et al. Prospective assessment of VI-RADS score in multiparametric MRI in bladder cancer: accuracy and the factors affecting the results. Diagn Interv Radiol. 2022;28(5):396–402.CrossRefPubMedPubMedCentral
32.
go back to reference Taguchi S, Watanabe M, Tambo M, Machida H, Yokoyama K, Fukuhara H. Proposal for a New Vesical Imaging-Reporting and Data System (VI-RADS)-Based Algorithm for the Management of Bladder Cancer: A Paradigm Shift From the Current Transurethral Resection of Bladder Tumor (TURBT)-Dependent Practice. Clin Genitourin Cancer. 2022;20(4):e291–5.CrossRefPubMed Taguchi S, Watanabe M, Tambo M, Machida H, Yokoyama K, Fukuhara H. Proposal for a New Vesical Imaging-Reporting and Data System (VI-RADS)-Based Algorithm for the Management of Bladder Cancer: A Paradigm Shift From the Current Transurethral Resection of Bladder Tumor (TURBT)-Dependent Practice. Clin Genitourin Cancer. 2022;20(4):e291–5.CrossRefPubMed
33.
go back to reference Ark JT, Keegan KA, Barocas DA, Morgan TM, Resnick MJ, You C, et al. Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. BJU Int. 2014;113(6):894–9.CrossRefPubMedPubMedCentral Ark JT, Keegan KA, Barocas DA, Morgan TM, Resnick MJ, You C, et al. Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. BJU Int. 2014;113(6):894–9.CrossRefPubMedPubMedCentral
Metadata
Title
MRI evaluation of vesical imaging reporting and data system for bladder cancer after neoadjuvant chemotherapy
Authors
Xinxin Zhang
Yichen Wang
Yilin Wang
Jie Zhang
Jin Zhang
Lianyu Zhang
Sicong Wang
Jianzhong Shou
Yan Chen
Xinming Zhao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Imaging / Issue 1/2024
Electronic ISSN: 1470-7330
DOI
https://doi.org/10.1186/s40644-024-00696-6

Other articles of this Issue 1/2024

Cancer Imaging 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine